Study Design
narcolepsy
NARCOLEPSY
REST-ON was a multicenter phase 3, randomized, double-blind, placebo-controlled clinical trial (NCT02720744). The trial was designed to evaluate the efficacy and safety of ON-SXB for the treatment of narcolepsy. Full details on the trial design were previously published [REST-ON was approved by institutional review boards at participating centers and conducted in compliance with the ethical principles of the Declaration of Helsinki, Good Clinical Practice guidelines, International Council for Harmonisation guidelines, and applicable national and local laws and regulatory requirements. Before participation in the study, participants provided written informed consent. For patients aged 16 or 17 years, consent was obtained from both the patient and their legal, authorized guardian [